Comments
Orchid Pharma shares hit a fresh life-time high on Wednesday after the Chennai-based drug marker announced signing of a technology transfer agreement with a multinational biotechnology firm for one of its projects.
On Tuesday, Orchid Pharma announced that it has entered into a technology transfer agreement with a leading multinational biotechnology company for its fermentation-based ‘7ACA project’ under the production-linked incentive (PLI) scheme. The name of the biotechnology firm and other terms of the agreement were not disclosed. 7-ACA (7-aminocephalosporanic acid) is the core chemical structure used for the synthesis of cephalosporin antibiotics and intermediates.
Shares of Orchid Pharma hit a 52-week high ₹525 on intra-day on NSE against the previous day’s closing price of ₹501.40. The stocks closed at ₹520, 4 per cent higher than Tuesday’s closing price.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.